Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia

Sleep

Volumn 32, Issue 6, 2009, Pages 817-824

  Snedecor, Sonya J ^a   Botteman, Marc F ^a   Bojke, Chris ^a   Schaefer, Kendyl ^b   Barry, Nadine ^b   Pickard, A Simon ^c  

^a PHARMERIT INTERNATIONAL   (United States)

^b SUNOVION PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Costs and cost analysis; Economic; Eszopiclone; Insomnia; Models; Public policy

Indexed keywords

ESZOPICLONE;

ABSENTEEISM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; EVENING DOSAGE; HEALTH CARE COST; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SHORT FORM 36; STATISTICAL MODEL; TREATMENT OUTCOME;

EID: 67049117585     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/32.6.817     Document Type: Article

References (60)

1. Hajak G. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci 2001;251:49-56. (Pubitemid 32488031)
2. Kapur VK, Redline S, Nieto FJ, Young TB, Newman AB, Henderson JA. The relationship between chronically disrupted sleep and healthcare use. Sleep 2002;25:289-296 (Pubitemid 34496410)
3. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002;51:229-235 (Pubitemid 34219685)
4. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population. J Gen Intern Med 1995;10:25-32.
5. Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med 2001;63:49-55. (Pubitemid 32125356)
6. Leger D, Guilleminault C, Bader G, Levy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep 2002;25:625-629 (Pubitemid 34977501)
7. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-1423 (Pubitemid 27415610)
8. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep 1999;22 Suppl 2:S379-S385. (Pubitemid 29293499)
9. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev 2004;8:63-72. (Pubitemid 38313381)
10. National health expenditure projections 2007-2017. http://wwwcmshhsgov/ NationalHealthExpendData/Downloads/proj2007pdf [serial online] 2007.
11. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs (Millwood) 2004; Web Exclusive.
12. Neumann PJ, Lin PJ, Greenberg D, et al. Do drug formulary policies reflect evidence of value? Am J Manag Care 2006;12:30-36.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258 (Pubitemid 26337709)
14. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics 1998;14:629-637
15. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22 Suppl 2:S386-S393.
16. Leger D, Levy E, Paillard M. The direct costs of insomnia in France. Sleep 1999;22 Suppl 2:S394-S401. (Pubitemid 29293501)
17. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004;65 Suppl 8:13-19.
18. Godet-Cayre V, Pelletier-Fleury N, Le VM, Dinet J, Massuel MA, Leger D. Insomnia and absenteeism at work. Who pays the cost? Sleep 2006;29:179-184
19. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-273 (Pubitemid 46494401)
20. Chevalier H, Los F, Boichut D et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 1999;13:S21-S24. (Pubitemid 30055121)
21. Reimer MA, Flemons WW. Quality of life in sleep disorders. Sleep Med Rev 2003;7:335-349 (Pubitemid 36935312)
22. Byles JE, Mishra GD, Harris MA. The experience of insomnia among older women. Sleep 2005;28:972-979 (Pubitemid 41170932)
23. Le GY, Gagnadoux F, Hureaux J, et al. Sleep disturbances and impaired daytime functioning in outpatients with newly diagnosed lung cancer. Lung Cancer 2007;58:139-143 (Pubitemid 47379971)
24. Technology Appraisal Guidance 77 Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of Insomnia Issue date: April 2004 Review date: April 2007. www.nice.org.uk/guidance/TA077 [serial online] 2007.
25. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049-1057
26. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007;21:319-334 (Pubitemid 46598451)
27. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799 (Pubitemid 39610622)
28. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-968 (Pubitemid 47221895)
29. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307. (Pubitemid 32677404)
30. Ware JE. SF-36 health survey: Manual and interpretation guide. Quality Metric Inc., 2003.
31. Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care 2001;39:72-85. (Pubitemid 33613284)
32. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-528
33. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342 (Pubitemid 30479101)
34. Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making 2004;24:247-254 (Pubitemid 38656308)
35. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics 1996;10 Suppl 1:1-14.
36. Metlaine A, Leger D, Choudat D. Socioeconomic impact of insomnia in working populations. Ind Health 2005;43:11-19. (Pubitemid 40260809)
37. Stoller MK. Economic effects of insomnia. Clin Ther 1994;16:873-897
38. Bureau of Labor Statistics. Employer costs for employee compensation-June 2006, Table. 1 - Employer costs per hour worked for employee compensation and costs as a percent of total compensation: Civilian workers, by major occupational and industry group, June 2006. US Department of Labor [serial online] 2006; Accessed December 7, 2007.
39. Bureau of Labor Statistics. The employment situation: October 2006. Table A. Major indicators of labor market activity, seasonally adjusted. Total private hours of work. US Department of Labor [serial online] 2007; Accessed December 7, 2007.
40. Bureau of Labor Statistics. Table A-13. Employment status of the civilian noninstitutional population by age, sex, and race. US Department of Labor [serial online] 2006; Accessed December 7, 2007.
41. Physician's desk reference red book 2006. Oxford: Blackwell; 2006.
42. Office of the Inspector General Medicaid Pharmacy. Actual Acquisition Cost of Prescription Drug Products for Brand Name Drugs. Department of Health and Human Services [serial online] 2007; Accessed September 13, 2007.
43. Novartis. Novartis pharmacy benefit report: facts & figures; 1999.
44. Ingenix. CPT Expert - 2006. Thomson Delmar Learning, 2005.
45. Thompson M, Gawel M, Desjardins B, Ferko N, Grima D. An economic evaluation of rizatriptan in the treatment of migraine. Pharmacoeconomics 2005;23:837-850 (Pubitemid 41420429)
46. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17:599-611. (Pubitemid 28499043)
47. McDonald H, Hux M, Brisson M, Bernard L, Nickel JC. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 2004;11:2327-2340
48. Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996;9:443-454 (Pubitemid 26141901)
49. Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005;45:1012-1022
50. Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics 2000;18:95-104.
51. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
52. Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ 1997;6:505-510 (Pubitemid 27474919)
53. Lichstein KL, Durrence HH, Bayen UJ, Riedel BW. Primary versus secondary insomnia in older adults: subjective sleep and daytime functioning. Psychol Aging 2001;16:264-271 (Pubitemid 32530288)
54. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997;17:1-9. (Pubitemid 27020134)
55. Lundberg L, Johannesson M, Isacson DG, Borgquist L. The relationship between health-state utilities and the SF-12 in a general population. Med Decis Making 1999;19:128-140 (Pubitemid 29318142)
56. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001;21:105-112 (Pubitemid 32318761)
57. Shmueli A. The relationship between the visual analog scale and the SF-36 scales in the general population: an update. Med Decis Making 2004;24:61-63. (Pubitemid 38116858)
58. Lawrence WF, Fleishman JA. Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Med Decis Making 2004;24:160-169 (Pubitemid 38391936)
59. Franks P, Lubetkin EI, Gold MR, Tancredi DJ. Mapping the SF-12 to preference-based instruments: convergent validity in a low-income, minority population. Med Care 2003;41:1277-1283
60. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-859 (Pubitemid 39456916)